This study is currently not recruiting participants.

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Investigating Treatments for Advanced Colorectal Cancer with DNA Repair Deficiency

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient DNA mismatch repair colorectal cancer that has spread to other places in the body.

Detailed description of study

The purpose of this study is to determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (mFOLFOX6)/bevacizumab plus atezolizumab (combination) and atezolizumab (single agent) as compared to mFOLFOX6/bevacizumab (control).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: colorectal cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates treatments for colorectal cancer that has spread to other parts of the body and involves a deficiency in DNA mismatch repair. DNA mismatch repair is a system within the cell that corrects errors that occur during DNA replication. The purpose of this study is to determine how well different treatment combinations work for this type of cancer.

Participants in the study will receive either a combination of chemotherapy drugs or a combination of chemotherapy and investigational medication. Some participants will receive an investigational medication alone. The study will compare these treatments to see which is more effective in delaying cancer progression.

  • Who can participate: Adults aged 18 and over diagnosed with colorectal cancer that has spread and involves deficient DNA mismatch repair are eligible to participate.
  • Study details: Participants will be randomly assigned to receive either a combination of chemotherapy drugs with or without investigational medication, or investigational medication alone.
Updated on 19 Feb 2024. Study ID: 1802094942 (NRG-GI004)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team